Literature DB >> 18534825

Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.

Thomas Tsaganos1, Pinelopi Kouki, Panagiotis Digenis, Helen Giamarellou, Evangelos J Giamarellos-Bourboulis, Kyriaki Kanellakopoulou.   

Abstract

The impact of intermittent haemodialysis (IHD) on the pharmacokinetics of levofloxacin after single and multiple oral doses of 500 mg was assessed in 10 patients with end-stage renal failure on IHD. In the first phase of the study where a single dose was administered, IHD was initiated 90 min after drug intake. In the second phase of the study where drug was administered daily for three consecutive days, IHD was started exactly after the first dose. Venous blood samples were collected at standard time intervals. Additional samples from the arterial and venous line of the fistula and from the dialysate were drawn at the first, second and fourth hour of the first IHD session. Levofloxacin concentrations were estimated by high performance liquid chromatography analysis using fluorescence detection. Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h. Removal of levofloxacin by IHD was indicated by a significant decrease in concentration from the arterial line to the venous line of the fistula. The C(max)/MIC and AUC(0-->24)/MIC ratios (where MIC is the minimum inhibitory concentration of the pathogen) remained above >100 and >10, respectively, rendering levofloxacin a candidate for infections in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18534825     DOI: 10.1016/j.ijantimicag.2008.02.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  2 in total

1.  [Pharmacotherapy in patients suffering from chronic kidney disease].

Authors:  J T Kielstein; F Keller
Journal:  Internist (Berl)       Date:  2012-07       Impact factor: 0.743

2.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.